

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **KRUSINGA** Examiner: Javanmard, Sahar
Serial No.: 10/529,341 Group Art Unit: To be assigned
Filed: February 13, 2006 Confirmation No.: 8991
For: **COMBINED USE OF METHYLPHENIDATE AND MELATONIN FOR
TREATING ATTENTION-DEFICIT HYPERACTIVE DISORDER**
Customer No.:

23719

PATENT TRADEMARK OFFICE

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

April 14, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

Sir:

This reply is to the Restriction Requirement mailed on December 13, 2007, in connection with the above-identified application. The time set for filing a response to the restriction requirement expired on January 13, 2008. Applicants hereby request a three-month extension of time under 37 CFR 1.136(a) and authorizes the Patent Office to charge the Deposit Account No. identified below. Accordingly, the period set to reply to the Office Action expired on April 13, 2008, which is a Sunday, and thus this reply is timely filed on Monday April 14, 2008.

Applicants provisionally elect, with traverse, the subject matter in Group II. Claim(s) 1-5 and 6-9 drawn to a method of preventing or treating ADHD disorder in a mammal, which comprises administering to said mammal a therapeutically effective amount of methylphenidate and one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof.

Applicants elect the species methylphenidate and melatonin.

Applicants respectfully reserve the right to pursue the claims not elected (group/species) in one or more divisional applications.